Novartis AG Company Profile (NYSE:NVS)

About Novartis AG (NYSE:NVS)

Novartis AG logoNovartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: N/A
  • Symbol: NYSE:NVS
  • CUSIP: N/A
  • Web: www.novartis.com
Capitalization:
  • Market Cap: $199.396 billion
  • Outstanding Shares: 2,365,595,000
Average Prices:
  • 50 Day Moving Avg: $83.03
  • 200 Day Moving Avg: $77.56
  • 52 Week Range: $66.93 - $86.90
P/E:
  • Trailing P/E Ratio: 30.74
  • Foreward P/E Ratio: 16.67
  • P/E Growth: 2.69
Sales & Book Value:
  • Annual Revenue: $49.18 billion
  • Price / Sales: 4.05
  • Book Value: $29.84 per share
  • Price / Book: 2.82
Dividend:
  • Annual Dividend: $2.30
  • Dividend Yield: 2.7%
Profitability:
  • EBIDTA: $14.45 billion
  • Net Margins: 13.52%
  • Return on Equity: 15.51%
  • Return on Assets: 8.41%
Debt:
  • Debt-to-Equity Ratio: 0.33%
  • Current Ratio: 1.01%
  • Quick Ratio: 0.75%
Misc:
  • Average Volume: 2.18 million shs.
  • Beta: 0.73
  • Short Ratio: 1.69
 
Frequently Asked Questions for Novartis AG (NYSE:NVS)

What is Novartis AG's stock symbol?

Novartis AG trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

How often does Novartis AG pay dividends? What is the dividend yield for Novartis AG?

Novartis AG announced an annual dividend on Friday, January 27th. Shareholders of record on Friday, March 3rd will be given a dividend of $2.327 per share on Friday, March 3rd. The ex-dividend date of this dividend is Wednesday, March 1st. View Novartis AG's Dividend History.

How will Novartis AG's stock buyback program work?

Novartis AG declared that its board has approved a stock buyback program on Saturday, April 8th 2017, which allows the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase up to 2.9% of its shares through open market purchases. Shares buyback programs are typically an indication that the company's board of directors believes its shares are undervalued.

How were Novartis AG's earnings last quarter?

Novartis AG (NYSE:NVS) issued its quarterly earnings data on Tuesday, July, 18th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.16 by $0.06. The firm earned $12.24 billion during the quarter, compared to the consensus estimate of $12.20 billion. Novartis AG had a net margin of 13.52% and a return on equity of 15.51%. Novartis AG's revenue was down 1.8% on a year-over-year basis. During the same period in the prior year, the business earned $1.23 EPS. View Novartis AG's Earnings History.

Where is Novartis AG's stock going? Where will Novartis AG's stock price be in 2017?

15 brokerages have issued 12 month target prices for Novartis AG's shares. Their predictions range from $74.37 to $92.00. On average, they expect Novartis AG's share price to reach $82.27 in the next year. View Analyst Ratings for Novartis AG.

Who are some of Novartis AG's key competitors?

Who are Novartis AG's key executives?

Novartis AG's management team includes the folowing people:

  • Joseph S. Jimenez, Chief Executive Officer, Member of the Executive Committee
  • Harry Kirsch, Chief Financial Officer, Member of the Executive Committee
  • Michael Ball, Chief Executive Officer of Alcon, Member of the Executive Committee
  • James Bradner M.D., President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee
  • Richard D. Francis, Chief Executive Officer of Sandoz Division, Member of the Executive Committee
  • Paul Hudson, Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive Committee
  • Bruno Strigini, Chief Executive Officer of Novartis Oncology, Member of the Executive Committee
  • Felix R. Ehrat Ph.D., Group General Counsel, Member of the Executive Committee
  • Steven Baert, Head of Human Resources, Member of the Executive Committee
  • Vasant Narasimhan M.D., Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee

Who owns Novartis AG stock?

Novartis AG's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (0.25%), Manning & Napier Advisors LLC (0.18%), Rockefeller Financial Services Inc. (0.04%), Aperio Group LLC (0.03%), Bartlett & Co. LLC (0.02%) and Douglas Lane & Associates LLC (0.02%). Company insiders that own Novartis AG stock include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Institutional Ownership Trends for Novartis AG.

Who sold Novartis AG stock? Who is selling Novartis AG stock?

Novartis AG's stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Advisors LLC, US Bancorp DE, Osborne Partners Capital Management LLC, Grimes & Company Inc., Tower Bridge Advisors, Douglas Lane & Associates LLC, Professional Advisory Services Inc. and Fulton Bank N.A.. View Insider Buying and Selling for Novartis AG.

Who bought Novartis AG stock? Who is buying Novartis AG stock?

Novartis AG's stock was bought by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Aperio Group LLC, Parkwood LLC, Chevy Chase Trust Holdings Inc., Pennsylvania Trust Co, TNB Financial, Texan Capital Management and Jarislowsky Fraser Ltd. Company insiders that have bought Novartis AG stock in the last two years include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Insider Buying and Selling for Novartis AG.

How do I buy Novartis AG stock?

Shares of Novartis AG can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novartis AG's stock price today?

One share of Novartis AG stock can currently be purchased for approximately $84.20.


MarketBeat Community Rating for Novartis AG (NYSE NVS)
Community Ranking:  2.3 out of 5 ( )
Outperform Votes:  224 (Vote Outperform)
Underperform Votes:  265 (Vote Underperform)
Total Votes:  489
MarketBeat's community ratings are surveys of what our community members think about Novartis AG and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Novartis AG (NYSE:NVS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 7 Hold Ratings, 6 Buy Ratings
Consensus Rating:Hold (Score: 2.27)
Consensus Price Target: $82.27 (2.29% downside)

Analysts' Ratings History for Novartis AG (NYSE:NVS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/26/2017Morgan StanleyUpgradeUnderweight -> OverweightLowView Rating Details
7/18/2017Cowen and CompanyReiterated RatingHoldLowView Rating Details
7/17/2017J P Morgan Chase & CoReiterated RatingNeutralLowView Rating Details
7/5/2017Credit Suisse GroupDowngradeNeutral -> Underperform$82.25MediumView Rating Details
6/22/2017Leerink SwannReiterated RatingMarket Perform$83.00LowView Rating Details
6/22/2017Barclays PLCUpgradeUnderweight -> Equal WeightLowView Rating Details
3/22/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutralLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageBuy -> BuyLowView Rating Details
3/7/2017Societe GeneraleUpgradeHold -> Buy$73.82 -> $74.37N/AView Rating Details
3/7/2017BNP ParibasDowngradeNeutral -> UnderperformN/AView Rating Details
1/31/2017ArgusUpgradeHold -> BuyN/AView Rating Details
1/17/2017Berenberg BankDowngradeBuy -> HoldN/AView Rating Details
1/9/2017Deutsche Bank AGReiterated RatingNeutralN/AView Rating Details
10/16/2016Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
10/10/2016Chardan CapitalLower Price TargetBuy$95.00 -> $92.00N/AView Rating Details
7/12/2016Bank of America CorporationReiterated RatingHoldN/AView Rating Details
5/24/2016Citigroup Inc.Reiterated RatingNeutralN/AView Rating Details
11/23/2015VontobelDowngradeHoldN/AView Rating Details
10/28/2015Sanford C. BernsteinLower Price TargetOutperform$102.00N/AView Rating Details
10/28/2015Main First Bank AGDowngradeUnderperformN/AView Rating Details
(Data available from 7/26/2015 forward)

Earnings

Earnings History for Novartis AG (NYSE:NVS)
Earnings by Quarter for Novartis AG (NYSE:NVS)
Earnings History by Quarter for Novartis AG (NYSE NVS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/18/2017Q2 17$1.16$1.22$12.20 billion$12.24 billionViewN/AView Earnings Details
4/25/20173/31/2017$1.10$1.13$11.59 billion$11.54 billionViewN/AView Earnings Details
1/25/2017Q416$1.12$1.12$12.44 billion$12.32 billionViewN/AView Earnings Details
10/25/2016Q316$1.19$1.23$12.24 billion$12.13 billionViewListenView Earnings Details
7/19/2016Q216$1.18$1.23$12.33 billion$12.47 billionViewListenView Earnings Details
4/21/2016Q116$1.18$1.17$11.90 billion$11.60 billionViewListenView Earnings Details
1/27/2016Q415$1.18$1.14$12.64 billion$12.52 billionViewListenView Earnings Details
10/27/2015Q315$1.31$1.27$12.66 billion$12.30 billionViewListenView Earnings Details
7/21/2015Q215$1.20$1.27$12.45 billion$12.70 billionViewListenView Earnings Details
4/23/2015Q115$1.12$1.33$12.90 million$11.94 billionViewN/AView Earnings Details
1/27/2015Q314$1.13$1.21$14.68 billion$14.63 billionViewN/AView Earnings Details
7/17/2014Q214$1.36$1.36$14.83 billion$14.64 billionViewN/AView Earnings Details
4/24/2014Q1 2014$1.33$1.31$14.25 billion$14.02 billionViewN/AView Earnings Details
1/29/2014Q413$1.27$1.20$15.16 billion$15.08 billionViewN/AView Earnings Details
10/22/2013Q313$1.31$1.26$14.28 billion$14.34 billionViewN/AView Earnings Details
7/17/2013Q213$1.29$1.30$14.39 billion$14.50 billionViewN/AView Earnings Details
4/24/2013Q113$1.28$1.32$14.02 million$14.02 billionViewN/AView Earnings Details
1/23/2013Q412$1.19$1.27$14.42 billion$14.80 billionViewN/AView Earnings Details
10/25/2012$1.34$1.34ViewN/AView Earnings Details
7/19/2012$1.33$1.38ViewN/AView Earnings Details
4/24/2012$1.30$1.27ViewN/AView Earnings Details
1/25/2012$1.26$1.23ViewN/AView Earnings Details
10/25/2011$1.45$1.45ViewN/AView Earnings Details
7/19/2011$1.46$1.48ViewN/AView Earnings Details
4/19/2011$1.30$1.41ViewN/AView Earnings Details
1/27/2011$1.25$1.14ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Novartis AG (NYSE:NVS)
2017 EPS Consensus Estimate: $4.75
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$1.08$1.15$1.12
Q2 20172$1.15$1.22$1.19
Q3 20171$1.25$1.25$1.25
Q4 20171$1.20$1.20$1.20
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Novartis AG (NYSE:NVS)
Most Recent Dividend:3/3/2017
Annual Dividend:$2.30
Dividend Yield:2.73%
Dividend Growth:3.90% (3 Year Average)
Payout Ratio:83.94% (Trailing 12 Months of Earnings)
48.52% (Based on This Year's Estimates)
45.54% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Novartis AG (NYSE:NVS)

Dividend History by Quarter for Novartis AG (NYSE NVS)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/27/2017Annual$2.333/1/20173/3/20173/3/2017
2/1/2016Annual$2.342/24/20162/26/20162/26/2016
2/4/2014annual$2.723.48%2/27/20143/3/20143/11/2014
2/11/2013annual$2.533.71%2/26/20132/28/20134/5/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Novartis AG (NYSE:NVS)
Insider Ownership Percentage: 0.01%
Institutional Ownership Percentage: 11.30%
Insider Trades by Quarter for Novartis AG (NYSE:NVS)
Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)
Insider Trades by Quarter for Novartis AG (NYSE:NVS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/5/2017Bioventures Ltd NovartisMajor ShareholderBuy266,667$15.00$4,000,005.00View SEC Filing  
5/11/2016Institutes For Biomed NovartisMajor ShareholderBuy277,777$18.00$4,999,986.00View SEC Filing  
2/17/2016Bioventures Ltd NovartisMajor ShareholderBuy375,000$8.00$3,000,000.00View SEC Filing  
9/22/2014Bioventures Ltd NovartisMajor ShareholderBuy325,000$15.00$4,875,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Novartis AG (NYSE:NVS)
Latest Headlines for Novartis AG (NYSE:NVS)
Source:
DateHeadline
americanbankingnews.com logoFY2017 Earnings Estimate for Novartis AG (NYSE:NVS) Issued By Jefferies Group
www.americanbankingnews.com - July 26 at 11:25 AM
americanbankingnews.com logoMorgan Stanley Upgrades Novartis AG (NVS) to Overweight
www.americanbankingnews.com - July 26 at 10:04 AM
finance.yahoo.com logoNovartis in 2Q17: Performance of Alcon
finance.yahoo.com - July 26 at 5:53 AM
finance.yahoo.com logoNovartis in 2Q17: Performance of Alcon
finance.yahoo.com - July 26 at 5:53 AM
americanbankingnews.com logoAnalysts Issue Forecasts for Novartis AG's FY2020 Earnings (NVS)
www.americanbankingnews.com - July 25 at 4:26 PM
finance.yahoo.com logoNovartis: Here’s What Impacted 2Q17 Earnings and Missed Estimates
finance.yahoo.com - July 25 at 6:18 AM
finance.yahoo.com logoForeign Exchange Impacts Novartis’s Growth in 2Q17
finance.yahoo.com - July 25 at 6:18 AM
finance.yahoo.com logo3 Key Things Every CAR-T Investor Should Watch
finance.yahoo.com - July 25 at 6:18 AM
finance.yahoo.com logoEarnings Review and Free Research Report: Novartis' EPS Grew 15% on Constant Currency Basis; Free Cash Flow Soared 28%
finance.yahoo.com - July 22 at 7:11 AM
finance.yahoo.com logoNovartis AG :NVS-US: Earnings Analysis: Q2, 2017 By the Numbers : July 20, 2017
finance.yahoo.com - July 22 at 7:11 AM
seekingalpha.com logoNovartis's Q2 Results: Encouraging Signals Fully Reflected In ... - Seeking Alpha
seekingalpha.com - July 22 at 7:11 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for Novartis AG Lifted by Analyst (NVS)
www.americanbankingnews.com - July 21 at 9:24 AM
thestreet.com logo5 New Breast Cancer Treatments That Are Helping to Save Lives ... - TheStreet.com
www.thestreet.com - July 21 at 5:03 AM
americanbankingnews.com logoResearch Analysts Set Expectations for Novartis AG's FY2020 Earnings (NVS)
www.americanbankingnews.com - July 20 at 2:50 PM
seekingalpha.com logoNovartis Will Hit $100 This Year - Seeking Alpha
seekingalpha.com - July 20 at 2:55 AM
investorplace.com logoNovartis AG (ADR) (NVS) Stock Pops on Solid Q2 Earnings - Investorplace.com
investorplace.com - July 19 at 12:36 AM
americanbankingnews.com logoNovartis AG (NVS) Receives "Hold" Rating from Cowen and Company
www.americanbankingnews.com - July 18 at 7:12 PM
investorplace.com logoNovartis AG (ADR) (NVS) Stock Pops on Solid Q2 Earnings
investorplace.com - July 18 at 2:05 PM
americanbankingnews.com logoNovartis AG (NVS) Releases Earnings Results, Beats Estimates By $0.06 EPS
www.americanbankingnews.com - July 18 at 12:13 PM
finanznachrichten.de logoNovartis Q2 Profit Rises; Confirms Full Year Guidance
www.finanznachrichten.de - July 18 at 6:50 AM
rttnews.com logoNovartis Q2 Profit Rises, Net Sales Down; Backs FY17 View
www.rttnews.com - July 18 at 6:50 AM
finance.yahoo.com logoNovartis CEO: About to enter next growth phase
finance.yahoo.com - July 18 at 6:50 AM
finance.yahoo.com logoNovartis Points to Early Signs of Rebound at Alcon Eye-Care Unit
finance.yahoo.com - July 18 at 6:50 AM
finance.yahoo.com logoNovartis net profit grows 10 percent in Q2, but sales dip
finance.yahoo.com - July 18 at 6:50 AM
finance.yahoo.com logoNovartis' CEO Says Getting Momentum Back in Alcon Unit
finance.yahoo.com - July 18 at 6:50 AM
finance.yahoo.com logoNovartis sees Alcon recovery opening door to spin-off IPO
finance.yahoo.com - July 18 at 6:50 AM
finance.yahoo.com logoNovartis Tops Q2 Earnings Estimate, Boosts Alcon Full Year Sales Guidance
finance.yahoo.com - July 18 at 6:50 AM
finance.yahoo.com logo2 Drug Giants In Buy Range: One Just Beat EPS Views, The Other Is On Tap
finance.yahoo.com - July 18 at 6:50 AM
finance.yahoo.com logoNovartis beats 2Q profit forecasts
finance.yahoo.com - July 18 at 6:50 AM
americanbankingnews.com logoJ P Morgan Chase & Co Reaffirms Neutral Rating for Novartis AG (NVS)
www.americanbankingnews.com - July 17 at 11:23 AM
finance.yahoo.com logoPfizer Is Set to Lose Its No. 1 Spot Among Drugmakers: Here's Why It Doesn't Matter
finance.yahoo.com - July 16 at 6:43 PM
americanbankingnews.com logoNovartis AG (NYSE:NVS) Expected to Post Quarterly Sales of $12.11 Billion
www.americanbankingnews.com - July 16 at 8:20 AM
seekingalpha.com logoNovartis' CAR Speeds Towards Approval With Panel Nod - Seeking Alpha
seekingalpha.com - July 15 at 7:03 AM
finance.yahoo.com logoCan Novartis (NVS) Spring a Surprise This Earnings Season?
finance.yahoo.com - July 15 at 7:03 AM
americanbankingnews.com logo$1.16 Earnings Per Share Expected for Novartis AG (NVS) This Quarter
www.americanbankingnews.com - July 14 at 4:35 PM
finance.yahoo.com logoFDA panel backs Novartis cancer drug
finance.yahoo.com - July 14 at 7:01 AM
finance.yahoo.com logoNovartis FDA Panel Approval: 'Pharma Innovation At Its Best'
finance.yahoo.com - July 14 at 7:01 AM
finance.yahoo.com logoCAR-Ts Clear One Roadblock But Face Many More
finance.yahoo.com - July 14 at 7:01 AM
finance.yahoo.com logoNovartis CAR-T Therapy Drug Recommended by FDA Panel
finance.yahoo.com - July 14 at 7:01 AM
rttnews.com logoNVS Gets Thumbs Up, Two Biosimilar Candidates To Face FDA Panel, VKTX On Track
www.rttnews.com - July 13 at 7:31 AM
finance.yahoo.com logoNovartis gets FDA panel recommendation for leukemia drug approval
finance.yahoo.com - July 13 at 7:31 AM
finance.yahoo.com logoRecommendation for Novartis May Give New Hope For Some Cancer Patients
finance.yahoo.com - July 13 at 7:31 AM
finance.yahoo.com logo[$$] FDA Panel Votes Unanimously to Support Leukemia Gene-Therapy Treatment
finance.yahoo.com - July 13 at 7:31 AM
finance.yahoo.com logoNovartis gets FDA panel approval for leukemia treatment
finance.yahoo.com - July 13 at 7:31 AM
finance.yahoo.com logoNovartis readies for FDA review of $1 bln CAR-T child cancer hope
finance.yahoo.com - July 12 at 6:32 AM
finance.yahoo.com logoLandmark Novartis Immunotherapy Faces Crucial FDA Hearing Wednesday
finance.yahoo.com - July 12 at 6:32 AM
finance.yahoo.com logo[$$] The Price Dilemma Over a $16,000 Drug
finance.yahoo.com - July 12 at 6:32 AM
americanbankingnews.com logoNovartis AG (NVS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - July 10 at 9:35 AM
americanbankingnews.com logoJefferies Group Brokers Lower Earnings Estimates for Novartis AG (NVS)
www.americanbankingnews.com - July 10 at 7:37 AM
americanbankingnews.com logoNovartis AG (NYSE:NVS) Rating Lowered to Underperform at Credit Suisse Group
www.americanbankingnews.com - July 9 at 9:40 PM

Social

Chart

Novartis AG (NVS) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by MarketBeat.com Staff